BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genocea Biosciences Lands Massive $35M Series B Round


1/3/2011 7:05:10 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced that it has closed a $35 million Series B round of venture financing, with new investors Johnson & Johnson Development Corporation (JJDC), Skyline Ventures and MP Healthcare Venture Management, Inc. (MPH) joining existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures. Stephen J. Hoffman, M.D., Ph.D., managing director at Skyline Ventures, joins the Genocea board in connection with the financing. In addition, Genocea also announced the appointment of industry veteran Seth Hetherington, M.D., to chief medical officer.

Proceeds will support Genocea as it enters clinical development for its lead program, a therapeutic vaccine for herpes simplex virus type 2 (HSV-2) infections. Genocea will also use funds to advance its deep research pipeline, including prophylactic vaccine programs addressing Chlamydia trachomatis, Streptococcus pneumoniae, HSV-2 and Plasmodium falciparum (malaria).

“We believe this substantial funding round validates the promise of our proprietary discovery platform and underscores the significant unmet medical need for new vaccines in our target diseases,” said Chip Clark, chief business officer of Genocea. “We are delighted to appoint Dr. Hetherington, who brings to Genocea invaluable vaccines, infectious diseases and drug development expertise. We look forward to applying his talents to further the development of our novel vaccines, which have the potential to benefit millions of patients worldwide.”

As chief medical officer, Dr. Hetherington will be responsible for all clinical, medical and regulatory activities. He brings to Genocea more than 25 years of experience in clinical drug development and academic medicine. Prior to joining Genocea, Dr. Hetherington was senior vice president, clinical and regulatory affairs at Icagen, a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. Earlier in his career, Dr. Hetherington was vice president, clinical development and chief medical officer at Inhibitex and served in positions of increasing responsibility in clinical drug development at GlaxoSmithKline and Glaxo Wellcome, where he made significant contributions to several clinical development programs, including the currently marketed pharmaceuticals Ziagen®, Trizivir® and Agenerase®. Dr. Hetherington currently serves as the industry representative to the Vaccines and Related Blood Products Advisory Committee of the U.S. Food and Drug Administration.

About Genocea

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell response helps confer protection. The company’s transformational discovery platform mines the natural immune response across diverse human populations in a way that radically reduces the risk, cost and time associated with antigen discovery. Genocea is currently developing vaccines for herpes simplex-2 (therapeutic and prophylactic), a sexually transmitted disease affecting roughly 15 percent of the U.S. population; Chlamydia trachomatis, a sexually transmitted disease agent causing an estimated 90 million cases worldwide; Streptococcus pneumoniae, the leading killer of children under the age of 5 worldwide; and Plasmodium falciparum (malaria), of which there are more than 100 million cases globally. Visit www.genocea.com for more information.


Read at BioSpace.com
Read at Mass High Tech
Read at Sun Herald

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES